Ana Bosch
Ana Bosch
Verified email at
Cited by
Cited by
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways
P Eroles, A Bosch, JA Pérez-Fidalgo, A Lluch
Cancer treatment reviews 38 (6), 698-707, 2012
Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research
A Bosch, P Eroles, R Zaragoza, JR Viña, A Lluch
Cancer treatment reviews 36 (3), 206-215, 2010
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer
A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ...
Science translational medicine 7 (283), 283ra51-283ra51, 2015
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer
M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ...
Science translational medicine 5 (196), 196ra99-196ra99, 2013
Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
J Staaf, D Glodzik, A Bosch, J Vallon-Christersson, C Reuterswärd, ...
Nature medicine 25 (10), 1526-1533, 2019
Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients
I Chirivella, B Bermejo, A Insa, A Pérez-Fidalgo, A Magro, S Rosello, ...
Breast cancer research and treatment 114, 479-484, 2009
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer
J Cortes, J Rodriguez, JM Aramendia, E Salgado, A Gurpide, ...
Oncology 64 (1), 28-35, 2002
Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
JJ Tao, P Castel, N Radosevic-Robin, M Elkabets, N Auricchio, N Aceto, ...
Science signaling 7 (318), ra29-ra29, 2014
Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy
C Saura, J Bendell, G Jerusalem, S Su, Q Ru, S De Buck, D Mills, ...
Clinical Cancer Research 20 (7), 1935-1945, 2014
Strategies to design clinical studies to identify predictive biomarkers in cancer research
JL Perez-Gracia, MF Sanmamed, A Bosch, A Patiño-Garcia, KA Schalper, ...
Cancer Treatment Reviews 53, 79-97, 2017
Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer
J Climent, J Perez-Losada, DA Quigley, IJ Kim, R Delrosario, KY Jen, ...
Journal of Clinical Oncology 28 (23), 3770, 2010
High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer
S Kimbung, B Lettiero, M Feldt, A Bosch, S Borgquist
Oncotarget 7 (37), 59640, 2016
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution …
P Martin-Martorell, S Rosello, E Rodriguez-Braun, I Chirivella, A Bosch, ...
British journal of cancer 99 (3), 455-458, 2008
MicroRNA profile in very young women with breast cancer
M Peña-Chilet, MT Martínez, JA Pérez-Fidalgo, L Peiró-Chova, SS Oltra, ...
BMC cancer 14, 1-14, 2014
Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?
JA Pérez-Fidalgo, P Pimentel, A Caballero, B Bermejo, JA Barrera, ...
The breast 20 (6), 548-554, 2011
The X-linked DDX3X RNA helicase dictates translation reprogramming and metastasis in melanoma
B Phung, M Cieśla, A Sanna, N Guzzi, G Beneventi, PCT Ngoc, M Lauss, ...
Cell reports 27 (12), 3573-3586. e7, 2019
Nitration of cathepsin D enhances its proteolytic activity during mammary gland remodelling after lactation
R Zaragozá, L Torres, C García, P Eroles, F Corrales, A Bosch, A Lluch, ...
Biochemical Journal 419 (2), 279-288, 2009
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: results from the Swedish PREDIX HER2 trial identifying …
JCS Bergh, A Andersson, J Bjohle, A Bosch, L Carlsson, AC Dreifaldt, ...
Journal of Clinical Oncology 37 (15_suppl), 501-501, 2019
Mechanisms of resistance to hormonal treatment in breast cancer
P Eroles, A Bosch, B Bermejo, A Lluch
Clinical and Translational Oncology 12, 246-252, 2010
Nitric oxide triggers mammary gland involution after weaning: remodelling is delayed but not impaired in mice lacking inducible nitric oxide synthase
R Zaragozá, A Bosch, C García, J Sandoval, E Serna, L Torres, ...
Biochemical Journal 428 (3), 451-462, 2010
The system can't perform the operation now. Try again later.
Articles 1–20